SEC Form 4											
FC	ORM 4	UNITED S	TATES SECURITIES AND EXCHANGE CO Washington, D.C. 20549	Vashington, D.C. 20549 NGES IN BENEFICIAL OWNERSHIP n 16(a) of the Securities Exchange Act of 1934 of the Investment Company Act of 1940 Id Ticker or Trading Symbol mology, Inc. [SANA] Transaction (Month/Day/Year) 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title other (specific below) EVP & President, R&D	TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						
Section 16. F	ox if no longer subject Form 4 or Form 5 hay continue. <i>See</i> (b).	to STATE	MENT OF CHANGES IN BENEFICIAL OWN Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940	Estimated average burden							
	dress of Reporting F		2. Issuer Name and Ticker or Trading Symbol Sana Biotechnology, Inc. [SANA]	(Check all applicab Director	le) 10% Owner						
(Last) C/O SANA B	(First) BIOTECHNOLO	(Middle) GY, INC.	3. Date of Earliest Transaction (Month/Day/Year) 03/07/2024	A below)	below)						
	LAINE STREET		4. If Amendment, Date of Original Filed (Month/Day/Year)	Line)							
(Street) SEATTLE	WA	98102		Form filed	, , ,						
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
Title of Security (Instr. 3)	Date	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
			Code	v	Amount	(A) or (D)	Price	 Reported Transaction(s) (Instr. 3 and 4) 		(Instr. 4)		

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number Derivative Securitie Acquired or Disposion of (D) (In 3, 4 and	e s I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Restricted Stock Units	(1)	03/07/2024		Α		67,083		(2)	(2)	Common Stock	67,083	\$0.00	67,083	D	
Stock Option (Right to Buy)	\$9.58	03/07/2024		A		301,875		(3)	03/06/2034	Common Stock	301,875	\$0.00	301,875	D	

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

2. The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

3. The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Remarks:

> /s/ Julie Shah, Attorney-in-Fact 03/08/2024 for Douglas E. Williams

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SEC F

1.

Date

of